Gayet-Ageron, Angèle <br/><br/>
The choice of the noninferiority margin in clinical trials was driven by baseline risk, type of primary outcome, and benefits of new treatment.  [electronic resource] 

 -  Journal of clinical epidemiology  Oct 2015 
 - 1144-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-5921 
<br/><br/><label>Standard No.: </label>10.1016/j.jclinepi.2015.01.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Confidence Intervals<br/>Cross-Sectional Studies<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Models, Statistical<br/>Randomized Controlled Trials as Topic<br/>Research Personnel--psychology<br/>Sample Size<br/>Surveys and Questionnaires<br/>Treatment Outcome